Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marta Gil

Showing results (211-220 of 229) with videos related to

Pageof 23
Sort By:
Orphanet Journal of Rare Diseases|February 28, 2021
Phenotypic characterization of X-linked hypophosphatemia in pediatric Spanish populationEnrique Rodríguez-Rubio, Helena Gil-Peña, Sara Chocron, et al.
JAMA Oncology|September 28, 2023
Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled TrialTae Won Kim, Philippe L Bedard, Patricia LoRusso, et al.
Journal for Immunotherapy of Cancer|March 26, 2022
Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumorsRocio Garcia-Carbonero, Miriam Bazan-Peregrino, Marta Gil-Martín, et al.
JACC. Basic to Translational Science|July 12, 2022
Specialized Proresolving Mediators Protect Against Experimental Autoimmune Myocarditis by Modulating Ca<sup>2+</sup> Handling and NRF2 ActivationAlmudena Val-Blasco, Patricia Prieto, Rafael Iñigo Jaén, et al.
International Journal of Molecular Sciences|January 21, 2023
Analysis of Differentially Expressed MicroRNAs in Serum and Lung Tissues from Individuals with Severe Asthma Treated with Oral GlucocorticoidsMarta Gil-Martínez, Clara Lorente-Sorolla, José M Rodrigo-Muñoz, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 8, 2026
Addressing unmet needs in long-term survivors of ovarian cancer (ENGOT ov40/NOGGO S13/GEICO 71-R/Expression VI): insights from a Spanish cohortMaria-Pilar Barretina-Ginesta, Ainhoa Madariaga, Marta Gil-Martín, et al.
BMC Cancer|July 22, 2024
ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancerAlexandra Leary, Purificación Estévez-García, Renaud Sabatier, et al.
BMC Medical Genetics|September 10, 2011
Genetic diagnosis of X-linked dominant Hypophosphatemic Rickets in a cohort study: tubular reabsorption of phosphate and 1,25(OH)2D serum levels are associated with PHEX mutation typeMarcos Morey, Lidia Castro-Feijóo, Jesús Barreiro, et al.
Nature Medicine|January 17, 2025
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trialAlicia F C Okines, Giuseppe Curigliano, Nobumasa Mizuno, et al.
European Journal of Cancer (Oxford, England : 1990)|April 10, 2026
Implementing a molecular prescreening strategy for tumors without public NGS access in a cancer center network: Results from the PREICO projectPaula Sàbat, Maria Ajenjo-Bauza, Cinta Hierro, et al.
Pageof 23

Showing results (211-220 of 229) with videos related to

Sort By:
Pageof 23
Orphanet Journal of Rare Diseases|February 28, 2021
Phenotypic characterization of X-linked hypophosphatemia in pediatric Spanish populationEnrique Rodríguez-Rubio, Helena Gil-Peña, Sara Chocron, et al.
JAMA Oncology|September 28, 2023
Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled TrialTae Won Kim, Philippe L Bedard, Patricia LoRusso, et al.
Journal for Immunotherapy of Cancer|March 26, 2022
Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumorsRocio Garcia-Carbonero, Miriam Bazan-Peregrino, Marta Gil-Martín, et al.
JACC. Basic to Translational Science|July 12, 2022
Specialized Proresolving Mediators Protect Against Experimental Autoimmune Myocarditis by Modulating Ca<sup>2+</sup> Handling and NRF2 ActivationAlmudena Val-Blasco, Patricia Prieto, Rafael Iñigo Jaén, et al.
International Journal of Molecular Sciences|January 21, 2023
Analysis of Differentially Expressed MicroRNAs in Serum and Lung Tissues from Individuals with Severe Asthma Treated with Oral GlucocorticoidsMarta Gil-Martínez, Clara Lorente-Sorolla, José M Rodrigo-Muñoz, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 8, 2026
Addressing unmet needs in long-term survivors of ovarian cancer (ENGOT ov40/NOGGO S13/GEICO 71-R/Expression VI): insights from a Spanish cohortMaria-Pilar Barretina-Ginesta, Ainhoa Madariaga, Marta Gil-Martín, et al.
BMC Cancer|July 22, 2024
ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancerAlexandra Leary, Purificación Estévez-García, Renaud Sabatier, et al.
BMC Medical Genetics|September 10, 2011
Genetic diagnosis of X-linked dominant Hypophosphatemic Rickets in a cohort study: tubular reabsorption of phosphate and 1,25(OH)2D serum levels are associated with PHEX mutation typeMarcos Morey, Lidia Castro-Feijóo, Jesús Barreiro, et al.
Nature Medicine|January 17, 2025
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trialAlicia F C Okines, Giuseppe Curigliano, Nobumasa Mizuno, et al.
European Journal of Cancer (Oxford, England : 1990)|April 10, 2026
Implementing a molecular prescreening strategy for tumors without public NGS access in a cancer center network: Results from the PREICO projectPaula Sàbat, Maria Ajenjo-Bauza, Cinta Hierro, et al.
Pageof 23